Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by several orders of magnitude. No technology currently exists that can sequence the amino acids of proteins at a single molecule level. To change this, Glyphic is developing a next generation […]

ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID’s aiSPIRE platform screens billions of antibody-target interactions while concurrently applying AI to reveal the history of immune responses in each patient. ImmuneID combines this proprietary data with deep patient-specific clinical findings and private and public […]

Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation and mutations.  Transcription factors (TFs) have long been the aspirational targets of drug developers, based on their central role in cancer and other diseases. TFs are DNA-binding proteins that can […]